The 2021 in-person Summit meeting is currently canceled in response to COVID-19 recommendations. In its place, in a manner similar to 2020, the Summit will be sponsoring a series of virtual meetings on topics of interest related to adult and influenza immunizations, and of course, the COVID-19 immunization programs.
Select a meeting title listed below to view a recording of each 2021 virtual event or to access individual presentations shared during the meeting. (Similar information is available for Summit meetings held during 2020.)
Be sure to check back on this page for announcements about upcoming webinars.
At this follow-up to two virtual meetings on COVID-19 vaccines conducted by the National Adult and Influenza Immunization Summit (NAIIS) in 2020, 8 vaccine manufacturers presented information on their COVID-19 vaccines and/or vaccine candidates in later clinical trial phases (Phase 2/3), as well as vaccines in earlier phases of clinical development. Information presented included (1) published or other data plus timing of next trial phases; (2) published Phase 2 data as well as a description and update on progress of Phase 3 trials; or (3) current vaccines and their roll out. Presenters also discussed the availability of doses over the next few months and provided an update on any other studies underway or planned. After the presentations, a moderated discussion was held including topics such as understanding SARS-CoV2 variants/mutations and their impact on vaccines, manufacturer thoughts about the duration of immunity and interruption of transmission, and answers to questions from attendees.
The meeting was moderated by Phyllis Arthur, Vice President, Infectious Diseases & Diagnostics Policy, at BIO. The Summit was delighted and grateful for the opportunity to collaborate with BIO on this important virtual meeting.